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doi:10.1016/j.pedneo.2011.11.007Background: Erythromycin is generally used as a prokinetic agent for the treatment of feeding
intolerance in preterm infants; however, results from previous studies significantly vary due to
different medication dosages, routes of administration, and therapy durations. The effective-
ness and safety of intermediate-dose oral erythromycin in very low birth weight (VLBW) infants
with feeding intolerance was examined in this study.
Methods: Between November 2007 and August 2009, 45 VLBW infants with feeding intolerance,
who were all at least 14 days old, were randomly allocated to a treatment group and admin-
istered 5 mg/kg oral erythromycin every 6 hours for 14 days (nZ 19). Another set of randomly
selected infants was allocated to the control group, which was not administered erythromycin
(nZ 26).
Results: The number of days required to achieve full enteral feeding (36.5 7.4 vs. 54.7 23.3
days, respectively; pZ 0.01), the duration of parenteral nutrition (p< 0.05), and the time
required to achieve a body weight 2500 g (p< 0.05) were significantly shorter in the erythro-
mycin group compared with the control group. The incidence of parenteral nutrition-
associated cholestasis (PNAC) and necrotizing enterocolitis (NEC)  stage II after 14 days of
treatment were significantly lower (p< 0.05) in the erythromycin group. No significant differ-
ences were observed in terms of the incidences of sepsis, bronchopulmonary dysplasia, or reti-
nopathy of prematurity. No adverse effects were associated with erythromycin treatment.t of Pediatrics, Chung Shan Medical University Hospital, No. 110, Chien-Kuo N. Road, Section 1,
.-Y. Chen).
an Pediatric Association. Published by Elsevier Taiwan LLC. All rights reserved.
Erythromycin in preterm with feeding intolerance 35Conclusions: Intermediate-dose oral erythromycin is effective and safe for the treatment of
feeding intolerance in VLBW infants. The incidences of PNAC and  stage II NEC were signifi-
cant lower in the erythromycin group.
Copyright ª 2012, Taiwan Pediatric Association. Published by Elsevier Taiwan LLC. All rights
reserved.1. Introduction
Premature, very low birth weight (VLBW) infants frequently
develop feeding intolerance. Neonatologists often choose
to withhold feeding or hesitate to advance daily feeding
volumes in these neonates. Full enteral feeding, with the
aim of delivering a total daily fluid intake of 150 mL/kg/
day, is difficult to achieve. Inadequate caloric intake can
result in postnatal growth restriction and hasten the
complications of parenteral nutrition.1
Although the exact mechanisms remain unclear, mac-
rolide antibiotic erythromycin has been used for decades as
a prokinetic agent to facilitate the advancement of enteral
feeding in preterm infants. Data from previous clinical
trials are inconsistent, possibly due to variations in times
and routes of erythromycin administration, as well as
varying durations of erythromycin therapy.2,3
In the past, metoclopramide or domperidone have been
prescribed to treat feeding intolerance in premature
infants. However, we were unable to treat refractory
gastrointestinal motility in a VLBW infant until intermediate-
dose oral erythromycin was administered on postnatal day
78. The time required to reach full enteral feeding after
beginning erythromycin therapy was 15 days. No adverse
effects were noted. Consequently, this prospective study
was conducted to determine the effectiveness and safety
of intermediate-dose oral erythromycin in VLBW infants
with feeding intolerance.
2. Patients and Methods
2.1. Patients
This study was approved by the institutional review board
of Chung Shan Medical University Hospital. Informed
consent was obtained from all parents before the study was
initiated. The trial was conducted at the neonatal intensive
care unit (NICU) of Chung Shan University Hospital. Infants
were eligible for this study if they met the following
criteria: (I) gestational age <32 weeks, (II) birth body
weight <1500 g, (III) had been receiving <50% of the total
daily fluid intake or <75 mL/kg/day of milk via oral feed-
ings after 14 days of life (DOL). Infants were excluded from
this study if they had major congenital malformations, such
as congenital heart disease (except persistent patent duc-
tus arteriosus or patent foramen ovale), gastrointestinal
anomalies, hypoxic injury, current or previous history of
necrotizing enterocolitis (NEC) within 7 days of the onset of
feeding intolerance, or suspected or confirmed sepsis. The
administration of other prokinetic agents or probiotics was
not allowed in the erythromycin group during the study
period.2.2. Sample size
The sample size was calculated based on the primary
outcome, i.e., the time required for the infant to tolerate
a full feeding. Our unit statistics revealed a consistently
high prevalence of milk intolerance in preterm VLBW
infants during the 2 consecutive years before this study was
initiated. The mean total time required to tolerate a full
enteral feedings in our unit was 50 days. Assuming that the
median time to full feeding was 33 days in the erythromycin
group, with an a-error of 0.05 (two-tailed) and a power of
detection of 0.9, a sample size of 30 subjects (15 in each
group) was required.
2.3. Medication
In the erythromycin group, the infants were given 5 mg/kg
of erythromycin estolate (Ulosina in an oral suspension
diluted to 20 mg/mL with sterile water; U-Liang Pharma-
ceutical Co., Ltd., Taiwan) every 6 hours for 14 days.
Erythromycin was administered 30 minutes before feeding.
Infants in the control group received 2 cc/kg of 5% dextrose
water when three feedings were attempted every 3 hours,
and then oral milk feedings were initiated. The medications
and dextrose water were suspended if oral feedings were
discontinued and then resumed afterward.
2.4. Enteral and parenteral nutrition
According to the NICU feeding protocol, parenteral fluids
with glucose are required to meet the immediate fluid and
energy requirements of all VLBW infants. Parenteral nutri-
tion solutions (e.g., glucose, amino acids, calcium, vita-
mins, etc.) were started on DOL 2, and a 20% intralipid
solution with trace elements of various supplements was
supplied on DOL 3. Oral milk feedings were usually started
at a volume of 10e20 mL/kg/day as soon as possible and
increased to 10e35 mL/kg/day unless feeding intolerance
was encountered.
The presence of any one of the following signs indicated
feeding intolerance: (I) emesis, (II) increased residual on
nasogastric (NG) aspiration (>50% of the previous feeding
or >30% of multiple previous feedings), (III) findings of
abdominal distention and tenderness on physical examina-
tion, or (IV) the presence of bloody stools.
Milk feedings were administered as a continuous infusion
under gravity through an orogastric tube or nasogastric tube
every 3 hours. The attending nurse aspirated the stomach
once every 3 hours to measure gastric residuals, and the
attending clinician would either withhold enteral feeding
altogether or discontinue the advancement of feeding if
intolerance was noted.
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Comparisons of continuous variables were made using two-
tailed independent samples, and the Student’s t test was
used to analyze normally distributed data. For comparisons
of the categorical data, the Chi-square test and Fisher’s
exact test were used whenever applicable. SPSS version
15.0 (SPSS Inc., Chicago, IL, USA) was used for all statistical
evaluations and the level of significance was set to
p< 0.05. All p values reported in this trial are two-tailed.3. Results
A total of 51 patients were initially enrolled in this study, of
which 25 were allocated to the erythromycin group and 26
were allocated to the control group. However, three infants
were withdrawn from the erythromycin group during the
study period due to parental concerns about the adverse
effects of the medication. Two infants in the erythromycin
group died and were excluded from this study because ofTable 1 Clinical characteristics of the oral erythromycin and c
Clinical characteristics Oral erythro
(nZ 19)
Gestational age (wk) 28.4 2.5
Birth weight (g) 1114.8 296
Male : female 9 (47.4%):10
Classified as small for the gestational age 3 (15.8%)
Mode of delivery (NSD:CS) 6 (31.6%):13
Surfactant used 9 (47.4%)
Umbilical arterial catheter 12 (63.2%)
duration (d) 3.7 3.7
Umbilical venous catheter 16 (84.2%)
duration (d) 4.7 3.4
Antenatal dexamethasone 14 (73.7%)
Apgar score
1 min 4.9 1.2
5 min 6.6 1.3
Arterial blood analysis
pH 7.3 0.1
Base excess (mmol/L) 3.2 3.4
First hematocrit after delivery (%) 47.1 6.6
Body temperature on admission (C) 35.4 0.7
CRIB score 4.9 5.0
NTISS 20.6 3.8
Oxygenation index at admission 3.8 3.5
PDA
At 72 h 9 (47.4%)
Indomethacin 6 (31.6%)
Ibuprofen 3 (15.8%)
PDA ligation 2 (10.5%)
Type of milk feedings (human milk/
formula milk/mixed)
8 / 4 / 7
(42.1%/ 21.1
Age at the beginning of enteral feeding (d) 5.7 3.6
CRIB scoreZ clinical risk index for babies score; CSZ cesarean sect
apeutic Intervention Scoring System; PDAZ patent ductus arteriosusparental refusal to allow their infants to receive further
treatment after the development of severe intraventricular
hemorrhage and periventricular leukomalacia, respec-
tively. Another infant was withdrawn after 1 day of eryth-
romycin treatment following a positive blood culture for
Streptococcus mitis. Therefore, 45 infants completed the
study. Nineteen infants received erythromycin treatment
and 26 were observed without erythromycin treatment.
There were no statistically significant differences
between the demographic data and clinical characteristics
of the two groups (Table 1). Both groups started enteral
feedings at a similar mean age.
The clinical outcomes are summarized in Table 2. All
infants in the erythromycin group received an unsus-
pended 14-day course of treatment over the course of the
study. In the erythromycin group, the mean time of
enrollment in the study was 21.9 7.7 DOL. The mean
volume of feeding at enrollment was 24.4 17.3 mL/kg/
day. The mean time required to reach full feeding after
the beginning of treatment in the erythromycin group was
14.6 4.1 days.ontrol groups.
mycin group Control group p
(nZ 26)
28.4 1.9 0.941
.0 1179.5 275.5 0.455
(52.6%) 12 (46.2%):14 (53.8%) 1
1 (3.8%) 0.295
(68.4%) 8 (30.8%):18 (69.2%) 1
16 (61.5%) 0.379
15 (57.7%) 1
3.7 3.6 0.974
20 (76.9%) 0.667
4.8 3.4 0.975
14 (53.8%) 0.222
4.0 1.8 0.081
6.4 1.4 0.482
7.3 0.1 0.893
4.6 3.5 0.196
45.9 6.6 0.555
35.4 0.7 0.86
5.0 2.9 0.967
20.7 4.1 0.935
3.7 3.1 0.887
13 (50%) 1
6 (23.1%) 0.734
9 (34.6%) 0.191
4 (15.4%) 1
% / 36.8%)
4 / 5 / 17
(15.4% / 19.2% / 65.4%)
0.099
6.0 4.5 0.811
ion; NSDZ normal spontaneous delivery; NTISSZ Neonatal Ther-
.
Table 2 Comparison of the clinical outcomes of the oral erythromycin and control groups.
Erythromycin
group (nZ 19)
Control group
(nZ 26)
p
Time enrolled the study (DOL)* 21.9 7.7 20.7 8.3 0.625
Mean volume of feeding at enrollment (mL/kg/d)* 24.4 17.3 34.8 22.9 0.103
Time to full feeding after the beginning of the study (d)* 14.6 4.1 34.0 23.2 0.01y
Time after birth required to achieve half enteral feeding (75 mL/kg/d) (d) 28 7.7 37.5 20.9 0.041y
Time after birth required to achieve 3/4 enteral feeding (115 mL/kg/d) (d) 33.0 7.6 47.2 22.1 0.005y
Time after birth required to achieve full enteral feeding (150 mL/kg/d) (d) 36.5 7.4 54.7 23.3 0.001y
Time required to regain birth body weight (d) 20.7 6.7 24.8 11.1 0.162
Duration of parenteral nutrition (d) 44.7 10.0 63.2 33.9 0.013y
Duration of lipid infusion (d) 24.2 10.5 29.0 15.6 0.253
Duration of mechanical ventilation (d) 33.4 25.5 27.7 25.4 0.462
Duration of O2 dependence (d) 49.6 32.0 48.7 38.4 0.934
Duration of aminophylline therapy (d) 55.6 23.2 56.1 34.5 0.961
NEC  stage IIa 0 (0%) 7 (26.9%) 0.016y
PNAC 2 (10.5%) 10 (38.5%) 0.046y
Sepsis 1 (5.3%) 0 (0%) 0.422
Suspected sepsis (CRP 2 mg/dL with unstable clinical status) 1 (5.3%) 5 (19.2%) 0.222
IVH
none or mild 16 (84.2%) 24 (92.3%) 0.636
severe 3 (15.8%) 2 (7.7%)
ROP with laser therapy 6 (31.6%) 9 (34.6%) 1
BPD 4 (21.1%) 9 (34.6%) 0.507
Time required to achieve body weight  2500 g (d) 80.9 25.9 105.0 40.5 0.037y
*Data presented as median SD (range).
yp< 0.05.
BPDZ bronchopulmonary dysplasia; DOLZ days of life; IVHZ intraventricular hemorrhage; NECZ necrotizing enterocolitis;
PNACZ parenteral nutrition-associated cholestasis (direct bilirubin > 2 mg/dL); ROPZ retinopathy of prematurity.
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ability to tolerate full enteral feedings (36.5 7.4 vs.
54.7 23.3 days, respectively; pZ 0.01). Although there
was no significant difference in terms of the number days
required to regain birth weight between the groups, the
duration of parenteral nutrition (44.7 10 vs. 63.2 33.9
days, respectively; p< 0.05) and the time required to
achieve a body weight 2500 g (80.9 25.9 days vs.
105.0 40.5 days, respectively; p< 0.05) were significantly
shorter in the erythromycin group than the control group.
The incidence of parenteral nutrition-associated chole-
stasis (PNAC) was significantly lower in the erythromycin
group (10.5% vs. 38.5%; p< 0.05). The incidence of NEC 
stage II after 14 days of treatment was also lower in the
erythromycin group (0% vs. 26.9%; p< 0.05).
Physiological dehydration is known to predominate in
preterm infants. However, there was no difference in body
weight gains between the two groups or the time requiredTable 3 Comparison of body weight gains in the erythromycin
Body weight gain (g/kg/d)
Before enrollment
Time after enrollment required to achieve full enteral feeding
Time required to achieve half an enteral feeding
Time after achieved half enteral feeding
*p< 0.05.to achieve a daily intake of 75 mL/kg/day. A significant
increase in weight gain did occur in the erythromycin group
during the time required to progress from 75 mL/kg/day to
full enteral feeding (15.9 5.1 g/kg/day vs. 11.1 5.9 g/
kg/day; pZ 0.007). The mean body weight of the eryth-
romycin group increased by 14.6 4.3 g/kg/day during the
14 days of treatment (Table 3).
The incidences of sepsis or suspected sepsis, broncho-
pulmonary dysplasia, and retinopathy of prematurity (ROP)
were similar in both groups. None of the typical adverse
effects associated with erythromycin treatment, such as
cardiac arrhythmia or infantile hypertrophic pyloric
stenosis, were encountered over the course of this study.
One infant in the erythromycin group and five infants in
the control group had elevated C-reactive protein (CRP)
levels (> 2 mg/dL) that were also accompanied by unstable
clinical findings; these infants were diagnosed with sus-
pected sepsis. One infant in the erythromycin groupand control groups.
Erythromycin
group (nZ 19)
Control group
(nZ 26)
p
0.1 4.5 -1.2 4.0 0.290
14.6 4.3 9.4 4.8 0.01*
3.3 2.7 2.7 2.4 0.387
15.9 5.1 11.1 5.9 0.007*
38 Y.-Y. Ng et aldeveloped septicemia related to a peripherally inserted
central catheter (PICC). The PICC tip culture, pleural
effusion culture, and blood culture were all positive for
Candida parapsilosis. No bacteria were isolated from the
control group.4. Discussion
Although the fetus is able to swallow amniotic fluid at as
early as 11e12 weeks of gestation, many premature
neonates (especially VLBW infants) cannot tolerate enteral
feedings.1 The functional immaturity of gastrointestinal
motility in premature infants often takes several days or
even weeks to resolve. Prolonged hyperalimentation in
preterm infants increases the risk of developing cholestatic
jaundice, liver impairment, rickets of prematurity, catheter-
related septicemia, and postnatal growth restriction.4e9
The current clinical approach for the management of
feeding intolerance in preterm infants includes withholding
feeding, decreasing the amount of milk intake, and diluting
enteral fluid mixtures.1 Reports on medical treatment are,
unfortunately, rather limited, as are reports on the efficacy
and safety of treatments involving preterm infants.
Cisapride was widely prescribed in the 1980s and early
1990s because of its gastroprokinetic effects, but was
withdrawn from the market in 2000 after reports of life-
threatening cardiovascular side effects such as prolonged
QT interval, ventricular arrhythmia, and torsade de
pointes.10,11 A prospective blinded study by Dubin et al
demonstrated a higher risk of a prolonged QTc interval and
arrhythmia in preterm infants.11
Metoclopramide, a dopamine receptor antagonist, can
effectively improving gastrointestinal motility by increasing
the pressure of the lower esophageal sphincter, thus
enhancing esophageal peristalsis and decreasing the
gastric-emptying time. However, the clinical utility of
metoclopramide is hampered by its potential extrapyra-
midal side effects, acute dystonic reactions, and irrita-
bility, particularly in children.12,13
Domperidone, another dopamine antagonist, acts on
the chemoreceptor trigger zone and affects the motor func-
tions of the stomach and small intestine.14 Unlike metoclo-
pramide, domperidoneminimally penetrates the blood-brain
barrier and is not believed to exert effects on the central
nervous system. Nevertheless, in premature infants, who
could potentially have a leaky blood-brain barrier, neuro-
logical reactions may occur.14,15 Several cases of arrhythmias
associated with domperidone therapy, including QT interval
prolongation, have been reported in infants as well.16,17
Therefore, domperidone should be used judiciously.
Erythromycin has been studied as a prokinetic agent for
over 20 years. A motilin receptor agonist that affects the
gut and gallbladder, erythromycin stimulates enteric nerves
and smooth muscle, increases antral motility (resulting in
strong, nonpropagating gastric contractions), and triggers
migrating motor complexes in newborns.18e21
Three studies on the use of intravenous (IV) erythro-
mycin as a prokinetic agent in preterm neonates have
been reported. As a prophylactic treatment, Stenson et al
failed to show any significant differences between IV
erythromycin (15 mg/kg/dose every 8 hours) and placebo interms of the days required to achieve full feedings.22 Cairns
et al reported no significant difference in the time required
to establish full enteral feedings when using IV erythro-
mycin (3 mg/kg/day every 6 hours) as a rescue therapy.23 A
preliminary observation by Su et al indicates a good
response to erythromycin treatment in VLBW infants with
feeding intolerance, as assessed by the daily net orogastric
balance after an IV loading dose of 30 mg/kg/day was
administered over a 3-day period followed by a mainte-
nance dose of 3e5 mg/kg once per day until full feedings
(100 mL/kg/day) were established.24
Using oral erythromycin as a prophylactic prokinetic
agent, Oei et al reported that low-dose erythromycin
(2.5 mg/kg every 6 hours) effectively facilitates enteral
feeding.25 Nonetheless, in a study by Patole et al, prophy-
lactic oral erythromycin at a dose of 12 mg/kg every 6 hours
(48 mg/kg/day) failed to reduce the time required to
establish full enteral feedings in preterm neonates who
were <32 weeks of age (pZ 0.60).26
Aly et al demonstrated that earlier full enteral feedings,
fewer episodes of gastric residuals, and a shorter duration
of parenteral nutrition result from the use of low-dose
erythromycin (1 mg/kg every 8 hours) in infants with
a gestational age >32 weeks. No effect was found in infants
with a gestational age 32 weeks.27
Nuntnarumit et al studied intermediate-dose erythro-
mycin therapy (10 mg/kg every 6 hours for 2 days, followed
by 4 mg/kg every 6 hours for another 5 days) in preterm
infants who were 35 weeks and observed a decrease in
the time required to establish full enteral feedings
compared with placebo (p< 0.001).28 However, these
infants were enrolled at an earlier age (DOL 6e8) compared
with our study population, and the effectiveness of Nunt-
narumit et al’s protocol on infants with severe feeding
intolerance remains unclear.
In a large randomized control trial, Ng et al demon-
strated that infants treated with high-dose oral erythro-
mycin (12.5 mg/kg every 6 hours for 14 days) achieved full
enteral nutrition earlier than the placebo group (p< 0.001)
and the duration of parenteral nutrition decreased by 10
days (p< 0.001).29
In 1999, Honein et al reported a cluster of seven cases of
pyloric stenosis that occurred among neonates who had
received erythromycin for pertussis prophylaxis.30 In 2002,
a large population-based study by Cooper et al reported
that infants treated with erythromycin during the first 2
weeks of life were at an 8-fold increased risk of developing
pyloric stenosis; no increased risk of pyloric stenosis was
found in infants exposed to erythromycin after DOL 13.31
Hence, in our study, oral erythromycin was given to
infants with feeding intolerance who were >14 days of
postnatal age. The association between erythromycin and
pyloric stenosis is still not fully understood. The motilino-
mimetic effects of erythromycin on antral smooth muscle
functions, such as the migratory motor complex (MMC), has
been proposed.32 Although MMC does not appear until week
35 of gestation, pyloric stenosis had been reported in an
extremely low birth weight infant who was exposed to
erythromycin.21,27,33
After considering the side effects of the antimicrobial
dose of erythromycin (40e50 mg/kg/day) in infants and the
poor effects of low-dose erythromycin (3e12 mg/kg/day)
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dose oral erythromycin (5 mg/kg every 6 hours for 14
days) was used in our study. Based on the protocol reported
by Ng et al in their high-dose erythromycin trial, we
administered erythromycin treatment for 2 weeks. The
results showed the earlier achievement of full enteral
nutrition (pZ 0.001) and a shorter duration of parenteral
nutrition (pZ 0.013) in the erythromycin group, which is
similar to the results obtained by Ng et al.
Parenteral nutrition remains the primary method for
treating feeding intolerance in preterm infants; however,
PNAC continues to be a major concern in infants who
require long-term parenteral feeding. Previous studies
indicate that 40e60% of infants on long-term total paren-
teral nutrition (TPN) will eventually develop hepatic
dysfunction.4 The factors that contribute to the develop-
ment of PNAC are most likely multifactorial and include the
lack of enteral stimulation, recurrent sepsis, intestinal
bacterial overgrowth leading to a reduction in gut hormone
secretion, and biliary stasis.4e7
Using high-dose oral erythromycin, Ng et al demonstrated
a lower incidence of PNAC in erythromycin-treated infants
compared with placebo-treated infants (pZ 0.03).29 Using
intermediate-dose oral erythromycin, a significantly lower
incidence of PNAC was also noted in our study (pZ 0.046).
Most previous studies have failed to show any significant
differences in the incidence of NEC; however, the study by
Patole et al reported NEC  stage II resolves after a stan-
dardized feeding regimen is implemented.27e29,34 In our
study, no infants in the erythromycin group, but seven
infants in the control group, developed NEC  stage II. No
infants required surgery.
Despite the earlier achievement of full enteral feeding,
previous studies have shown no significant difference in the
number of days required to regain birth weight, length of
hospitalization, and weight at discharge.27e29 In our study,
an earlier achievement of a body weight 2500 g (p< 0.05)
was observed in the erythromycin group. Daily weight gain
was also significantly improved after erythromycin treat-
ment compared with the control group (Figure 1).Figure 1 Mean body weight gain of the oral erythromycin
and control groups from birth until time required to achieve
a body weight  2500 g. Daily weight gain was significantly
higher in the erythromycin group compared with the control
group. The arrow indicates the mean age of all patients at the
beginning of the study.In conclusion, our findings suggest that oral erythro-
mycin, when administered at 5 mg/kg every 6 hours, may
be considered as an adequate, safe, and effective dose to
administer for the treatment of feeding intolerance in
VLBW infants. However, there are several limitations in this
study. First of all, only 45 VLBW infants from a single center
were enrolled in this study. The small number of partici-
pants may not be representative enough to generalize the
findings of this study to all VLBW infants. In addition to the
limited sample size, there is the potential for selection bias
in trials that are not double blinded. Consequently,
a multicenter, randomized, controlled study on the effects
of intermediate-dose oral erythromycin on VLBW infants
with feeding intolerance is necessary.Acknowledgments
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